Interruption of Maternal to Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin

摘要

This randomized double-blind, placebo-controlled trial of HBIG of the prevention of vertical transmission of hepatitis B in Taiwan began in July 1978. By June 30, 1979, 89 babies of high titer HBsAg positive women have begun the following series: (a) placebo, (b) 1.0 cc HBIG at birth, or (c) 0.5 cc HBIG at birth, three and six months. Another 111 babies should be enrolled by August 1980 in order to meet the project goal of 200 babies. Unless unexpected problems arise this goal can be accomplished. Mean age of babies at time of their first injection was 45 minutes. Follow-up has been excellent so far with only two babies lost. Follow-up has been too short to assess the long term effects of HBIG treatment, but HBsAg positivity rate is not inconsistent with protection. No adverse reactions have been observed. Jaundice and elevated transaminase occurred in one baby 44 days ago who had received placebo.